Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
 
 

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

 
News
 
 
Language
 
Wednesday, August 17. 2016
 
  • Basilea extending its agreement with Hikma to include antifungal CRESEMBA® in addition to antibiotic Zevtera®
 
more...
 
Monday, August 15. 2016
 
  • Antifungal CRESEMBA® (isavuconazole) launched in first European markets
  • Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole (European trade name Zevtera® or Mabelio®)
  • Half-year cash and financial investments of CHF 311 million
 
more...
 
Monday, June 27. 2016
 
Basel, Switzerland, June 27, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that it has launched its new azole antifungal CRESEMBA® (isavuconazole) in Italy and will sponsor today a continuing medical education event on current challenges and recent developments in the management of invasive fungal infections in Bologna, Italy. The event will be co-chaired by Prof. Claudio Viscoli MD, Professor of Infectious Diseases, University of Genova and Prof. Corrado Girmenia MD, Professor of Haematology, Sapienza University of Rome.
 
more...
 
Thursday, June 09. 2016
 
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
 
more...
 
Info
 
 
 

Quick links:

Investor calendar
Upcoming events
 


News subscription
Press releases via e-mail
 


French Sunshine Act
Transparence des liens d’intérêt